54325 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Jul 07
17:19 UTC
|
RYAN
Ryan Specialty
|
◎ Target | Alex Scott ★★★☆☆ #1864 | Overweight | $39.00→ $46.00+17.9% |
|
Jul 07
17:19 UTC
|
RNR
RenaissanceRe
|
◎ Target | Alex Scott ★★★☆☆ #1864 | Equal Weight | $328.00→ $341.00+4.0% |
|
Jul 07
17:19 UTC
|
RKT
Rocket Companies
|
◎ Target | Terry Ma ★★☆☆☆ #2506 | Overweight | $19.00→ $17.00-10.5% |
|
Jul 07
17:19 UTC
|
RGA
Reinsurance Group of America
|
◎ Target | Alex Scott ★★★☆☆ #1864 | Overweight | $268.00→ $278.00+3.7% |
|
Jul 07
17:19 UTC
|
RARE
Ultragenyx Pharmaceutical
|
◎ Target | Luca Issi ★★★☆☆ #1373 | Outperform | $35.00→ $40.00+14.3% |
|
Jul 07
17:19 UTC
|
PRU
Prudential Financial
|
◎ Target | Alex Scott ★★★☆☆ #1864 | Underweight | $90.00→ $92.00+2.2% |
|
Jul 07
17:19 UTC
|
PLGO
Fidelis Insurance
|
◎ Target | Alex Scott ★★★☆☆ #1864 | Equal Weight | $22.00→ $24.00+9.1% |
|
Jul 07
17:19 UTC
|
ONC
BeOne Medicines
|
◎ Target | Leonid Timashev ★★☆☆☆ #2314 | Outperform | $436.00→ $451.00+3.4% |
|
Jul 07
17:19 UTC
|
NUVB
Nuvation Bio
|
◎ Target | Leonid Timashev ★★☆☆☆ #2314 | Outperform | $20.00→ $19.00-5.0% |
|
Jul 07
17:19 UTC
|
MRNA
Moderna
|
◎ Target | Luca Issi ★★★☆☆ #1373 | Sec→ r Perform | $38.00→ $45.00+18.4% |
|
Jul 07
17:19 UTC
|
MIRM
Mirum Pharmaceuticals
|
◎ Target | Lisa Walter ★★☆☆☆ #2771 | Outperform | $142.00→ $148.00+4.2% |
|
Jul 07
17:19 UTC
|
MANE
Veradermics
|
◎ Target | Roger Song ★★★★☆ #532 | Buy | $138.00→ $182.00+31.9% |
|
Jul 07
17:19 UTC
|
LEGN
Legend Biotech
|
◎ Target | Leonid Timashev ★★☆☆☆ #2314 | Outperform | $64.00→ $63.00-1.6% |
|
Jul 07
17:19 UTC
|
IDYA
IDEAYA Biosciences
|
◎ Target | Leonid Timashev ★★☆☆☆ #2314 | Outperform | $53.00→ $48.00-9.4% |
|
Jul 07
17:19 UTC
|
FLG
Flagstar Bank, National Association
|
◎ Target | Jared Shaw ★★☆☆☆ #2545 | Overweight | $16.00→ $17.00+6.2% |
|
Jul 07
17:19 UTC
|
FIBK
First Interstate BancSystem
|
◎ Target | Jared Shaw ★★☆☆☆ #2545 | Equal Weight | $36.00→ $38.00+5.6% |
|
Jul 07
17:19 UTC
|
EXEL
Exelixis
|
◎ Target | Leonid Timashev ★★☆☆☆ #2314 | Sec→ r Perform | $43.00→ $46.00+7.0% |
|
Jul 07
17:19 UTC
|
DAN
Dana
|
◎ Target | firm only | Buy | $40.00→ $39.00-2.5% |
|
Jul 07
17:19 UTC
|
CYTK
Cytokinetics
|
◎ Target | Leonid Timashev ★★☆☆☆ #2314 | Outperform | $119.00→ $117.00-1.7% |
|
Jul 07
17:19 UTC
|
CRMD
CorMedix
|
◎ Target | Leonid Timashev ★★☆☆☆ #2314 | Outperform | $14.00→ $13.00-7.1% |
|
Jul 07
17:19 UTC
|
CMPS
Compass Pathways
|
◎ Target | Thomas Shrader ★★★☆☆ #1931 | Buy | $14.00→ $25.00+78.6% |
|
Jul 07
17:19 UTC
|
BMRN
BioMarin Pharmaceutical
|
◎ Target | Luca Issi ★★★☆☆ #1373 | Sec→ r Perform | $66.00→ $62.00-6.1% |
|
Jul 07
17:19 UTC
|
AXSM
Axsome Therapeutics
|
◎ Target | Leonid Timashev ★★☆☆☆ #2314 | Outperform | $302.00→ $304.00+0.7% |
|
Jul 07
17:19 UTC
|
ASND
Ascendis Pharma A/S
|
◎ Target | Luca Issi ★★★☆☆ #1373 | Outperform | $275.00→ $280.00+1.8% |
|
Jul 07
17:19 UTC
|
ARGX
argenex
|
◎ Target | Luca Issi ★★★☆☆ #1373 | Outperform | $890.00→ $945.00+6.2% |
|
Jul 07
17:19 UTC
|
MGM
MGM Resorts International
|
↑ Upgrade | Trey Bowers ★★★☆☆ #1920 | Underweight→ Equal Weight | $48.30 |
|
Jul 07
17:19 UTC
|
DTRUY
Daimler Truck
|
↑ Upgrade | firm only | Overweight | |
|
Jul 07
16:19 UTC
|
VRTX
Vertex Pharmaceuticals
|
◎ Target | Brian Abrahams ★★☆☆☆ #2651 | Outperform | $543.00→ $570.00+5.0% |
|
Jul 07
16:19 UTC
|
UPBD
Upbound Group
|
◎ Target | Hoang Nguyen ★★★★☆ #698 | Buy | $28.00→ $29.00+3.6% |
|
Jul 07
16:19 UTC
|
REGN
Regeneron Pharmaceuticals
|
◎ Target | Brian Abrahams ★★☆☆☆ #2651 | Sec→ r Perform | $707.00→ $696.00-1.6% |
|
Jul 07
16:19 UTC
|
PTCT
PTC Therapeutics
|
◎ Target | Brian Abrahams ★★☆☆☆ #2651 | Sec→ r Perform | $82.00→ $85.00+3.7% |
|
Jul 07
16:19 UTC
|
OMF
OneMain
|
◎ Target | Moshe Orenbuch ★★☆☆☆ #2295 | Buy | $66.00→ $68.00+3.0% |
|
Jul 07
16:19 UTC
|
NBIX
Neurocrine Biosciences
|
◎ Target | Brian Abrahams ★★☆☆☆ #2651 | Outperform | $183.00→ $195.00+6.6% |
|
Jul 07
16:19 UTC
|
INCY
Incyte
|
◎ Target | Brian Abrahams ★★☆☆☆ #2651 | Sec→ r Perform | $95.00→ $99.00+4.2% |
|
Jul 07
16:19 UTC
|
GILD
Gilead Sciences
|
◎ Target | Brian Abrahams ★★☆☆☆ #2651 | Sec→ r Perform | $122.00→ $120.00-1.6% |
|
Jul 07
16:19 UTC
|
FCFS
FirstCash
|
◎ Target | Moshe Orenbuch ★★☆☆☆ #2295 | Buy | $235.00→ $240.00+2.1% |
|
Jul 07
16:19 UTC
|
ENVA
Enova International
|
◎ Target | Moshe Orenbuch ★★☆☆☆ #2295 | Buy | $190.00→ $250.00+31.6% |
|
Jul 07
16:19 UTC
|
BIIB
Biogen
|
◎ Target | Brian Abrahams ★★☆☆☆ #2651 | Outperform | $227.00→ $242.00+6.6% |
|
Jul 07
16:19 UTC
|
BCRX
BioCryst Pharmaceuticals
|
◎ Target | Brian Abrahams ★★☆☆☆ #2651 | Outperform | $13.00→ $14.00+7.7% |
|
Jul 07
16:19 UTC
|
AGIO
Agios Pharmaceuticals
|
◎ Target | Luca Issi ★★★☆☆ #1373 | Sec→ r Perform | $28.00→ $32.00+14.3% |
|
Jul 07
16:19 UTC
|
ACAD
ACADIA Pharmaceuticals
|
◎ Target | Brian Abrahams ★★☆☆☆ #2651 | Outperform | $29.00→ $36.00+24.1% |
|
Jul 07
16:19 UTC
|
MTH
Meritage Homes
|
↓ Downgrade | Ivy Zelman not yet tracked | Outperform→ Neutral | |
|
Jul 07
16:19 UTC
|
MHO
M/I Homes
|
↓ Downgrade | Ivy Zelman not yet tracked | Outperform→ Neutral | |
|
Jul 07
16:19 UTC
|
CCS
Century Communities
|
↓ Downgrade | Ivy Zelman not yet tracked | Neutral→ Underperform | |
|
Jul 07
16:19 UTC
|
NVR
NVR
|
↑ Upgrade | Ivy Zelman not yet tracked | Hold→ Buy | |
|
Jul 07
16:19 UTC
|
DHI
D.R. Horton
|
↑ Upgrade | Ivy Zelman not yet tracked | Neutral→ Outperform | |
|
Jul 07
15:18 UTC
|
WFC
Wells Fargo & Company
|
◎ Target | Ebrahim Poonawala ★★★☆☆ #1726 | Buy | $95.00→ $102.00+7.4% |
|
Jul 07
15:18 UTC
|
TMUS
T-Mobile US
|
◎ Target | Benjamin Swinburne ★★★★★ #163 | Overweight | $260.00→ $230.00-11.5% |
|
Jul 07
15:18 UTC
|
TGTX
TG Therapeutics
|
◎ Target | Alec Stranahan ★★☆☆☆ #2345 | Underperform | $17.00→ $20.00+17.6% |
|
Jul 07
15:18 UTC
|
T
AT&T
|
◎ Target | Simon Flannery not yet tracked | Overweight | $30.00→ $25.00-16.7% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.